Evidence map›Paper›PMID 30879288›Full record

ArticleThe Korean journal of internal medicine2021

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2.

Sung Yong Han, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Sung Ik Pyeon, Young Joo Park, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sung Yong HanDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Hyun Young WooDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Jeong HeoDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Sang Gyu ParkDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Sung Ik PyeonDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Young Joo ParkDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Dong Uk KimDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Gwang Ha KimDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Hyung Hoi KimMedical Research Institute, Pusan National University Hospital, Busan, Korea.
Geun Am SongDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Mong ChoDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Pusan National University Hospital · KRPusan National University · KR

Funding

Pusan National University
6 · The paper itself

Abstract

BACKGROUND/

aimsReal-world, clinical practice data are lacking about sofosbuvir/ ribavirin (SOF/RBV) treatment of Korean patients with hepatitis C virus genotype 2 (HCV GT2) infection. This study investigated the efficacy and safety of SOF/RBV in Korean patients with HCV GT2 infection and clinical factors predicting sustained virological response 12 weeks (SVR12) after the end of SOF/RBV treatment.

methodsA total of 181 patients with HCV GT2 with/without cirrhosis were treated with SOF/RBV for 16/12 weeks. Rapid virological response (RVR) was defined as non-detectable HCV RNA at 4 weeks.

resultsThe RVR rate was 80.7% (146/181), the end of treatment response rate was 97.8% (177/181) and the SVR12 rate was 92.8% (168/181). Of eight patients with relapse, four did not achieve RVR. Three patients had a history of hepatocellular carcinoma (HCC). Multivariable analysis showed that RVR (p = 0.015) and no previous history of HCC (p = 0.007) were associated with SVR12. Factors significantly contributing to RVR included cirrhosis, creatinine concentration, and pre-treatment HCV RNA level. SVR12 rate was significantly higher in RVR (+) than RVR (-) patients (95.2% vs. 82.9%, p = 0.011) and also significantly higher in patients without than with a history of HCC (94.1% vs. 72.7%, p = 0.008). During treatment, 80/181 patients (44.2%) experienced mild to moderate adverse events, with 32 (17.7%) requiring RBV dose reductions due to anemia.

conclusionSOF/RBV treatment was effective and tolerable in HCV GT2 patients. RVR and no previous history of HCC were positive predictors of SVR12.

Indexed as

Carcinoma, HepatocellularHepatitis C, ChronicLiver NeoplasmsAntiviral AgentsDrug Therapy, CombinationGenotypeHepacivirusHumansLiver CirrhosisNeoplasm Recurrence, LocalRibavirinSofosbuvirTreatment OutcomeAntiviral AgentsRibavirinSofosbuvirCarcinoma, hepatocellularHepatitis C, chronicRapid virological responseSofosbuvirSustained virological response

Identifiers

PMID30879288
PMCPMC8137398
OpenAlexW2921312861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.